These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35280373)

  • 1. Population pharmacokinetics of polymyxin B: a systematic review.
    Chen N; Guo J; Xie J; Xu M; Hao X; Ma K; Rao Y
    Ann Transl Med; 2022 Feb; 10(4):231. PubMed ID: 35280373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation and Validation of the Limited Sampling Strategy of Polymyxin B in Patients with Multidrug-Resistant Gram-Negative Infection.
    Li X; Zhang B; Cheng Y; Chen M; Lin H; Huang B; Que W; Liu M; Zhou L; Weng Q; Zhang H; Qiu H
    Pharmaceutics; 2022 Oct; 14(11):. PubMed ID: 36365141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy.
    Isla A; Rodríguez-Gascón A; Trocóniz IF; Bueno L; Solinís MA; Maynar J; Sánchez-Izquierdo JA; Pedraz JL
    Clin Pharmacokinet; 2008; 47(3):173-80. PubMed ID: 18307371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using machine learning to optimize antibiotic combinations: dosing strategies for meropenem and polymyxin B against carbapenem-resistant Acinetobacter baumannii.
    Smith NM; Lenhard JR; Boissonneault KR; Landersdorfer CB; Bulitta JB; Holden PN; Forrest A; Nation RL; Li J; Tsuji BT
    Clin Microbiol Infect; 2020 Sep; 26(9):1207-1213. PubMed ID: 32061797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
    Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
    Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Experience with High-Dose Polymyxin B against Carbapenem-Resistant Gram-Negative Bacterial Infections-A Cohort Study.
    Cai Y; Leck H; Tan RW; Teo JQ; Lim TP; Lee W; Chlebicki MP; Kwa AL
    Antibiotics (Basel); 2020 Jul; 9(8):. PubMed ID: 32726974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe Infusion-Related Adverse Events and Renal Failure in Patients Receiving High-Dose Intravenous Polymyxin B.
    John JF; Falci DR; Rigatto MH; Oliveira RD; Kremer TG; Zavascki AP
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel decoy strategy for polymyxin resistance in
    Park J; Kim M; Shin B; Kang M; Yang J; Lee TK; Park W
    Elife; 2021 Jun; 10():. PubMed ID: 34180396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetics and Limited Sampling Strategy for Therapeutic Drug Monitoring of Polymyxin B in Chinese Patients With Multidrug-Resistant Gram-Negative Bacterial Infections.
    Wang P; Zhang Q; Zhu Z; Feng M; Sun T; Yang J; Zhang X
    Front Pharmacol; 2020; 11():829. PubMed ID: 32581795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B.
    Rigatto MH; Oliveira MS; Perdigão-Neto LV; Levin AS; Carrilho CM; Tanita MT; Tuon FF; Cardoso DE; Lopes NT; Falci DR; Zavascki AP
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2443-9. PubMed ID: 26856846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods.
    Nelson BC; Eiras DP; Gomez-Simmonds A; Loo AS; Satlin MJ; Jenkins SG; Whittier S; Calfee DP; Furuya EY; Kubin CJ
    Antimicrob Agents Chemother; 2015 Nov; 59(11):7000-6. PubMed ID: 26324272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic Evaluation of MRX-8, a Novel Polymyxin, in the Neutropenic Mouse Thigh and Lung Infection Models against Gram-Negative Pathogens.
    Lepak AJ; Wang W; Andes DR
    Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32868332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of heme oxygenase-1 in polymyxin B-induced nephrotoxicity in rats.
    Dezoti Fonseca C; Watanabe M; Vattimo Mde F
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5082-7. PubMed ID: 22802257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephrotoxicity Associated with Intravenous Polymyxin B Once- versus Twice-Daily Dosing Regimen.
    Okoduwa A; Ahmed N; Guo Y; Scipione MR; Papadopoulos J; Eiras DP; Dubrovskaya Y
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PKPD Modeling of the Inoculum Effect of
    Chauzy A; Akrong G; Aranzana-Climent V; Moreau J; Prouvensier L; Mirfendereski H; Buyck JM; Couet W; Marchand S
    Front Pharmacol; 2022; 13():842921. PubMed ID: 35370719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Semi-mechanistic PK/PD modelling of combined polymyxin B and minocycline against a polymyxin-resistant strain of Acinetobacter baumannii.
    Aranzana-Climent V; Buyck JM; Smani Y; Pachón-Diaz J; Marchand S; Couet W; Grégoire N
    Clin Microbiol Infect; 2020 Sep; 26(9):1254.e9-1254.e15. PubMed ID: 32006693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymyxin B and fosfomycin thwart KPC-producing Klebsiella pneumoniae in the hollow-fibre infection model.
    Bulman ZP; Zhao M; Satlin MJ; Chen L; Kreiswirth BN; Walsh TJ; Nation RL; Li J; Tsuji BT
    Int J Antimicrob Agents; 2018 Jul; 52(1):114-118. PubMed ID: 29486233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes and safety of polymyxin B in the treatment of carbapenem-resistant Gram-negative bacterial infections: a real-world multicenter study.
    Zhang X; Qi S; Duan X; Han B; Zhang S; Liu S; Wang H; Zhang H; Sun T
    J Transl Med; 2021 Oct; 19(1):431. PubMed ID: 34656132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens.
    Sandri AM; Landersdorfer CB; Jacob J; Boniatti MM; Dalarosa MG; Falci DR; Behle TF; Bordinhão RC; Wang J; Forrest A; Nation RL; Li J; Zavascki AP
    Clin Infect Dis; 2013 Aug; 57(4):524-31. PubMed ID: 23697744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation.
    Kidd JM; Sakon CM; Oleksiuk LM; Cies JJ; Pettit RS; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31685468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.